Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 14;195(44):E1509.
doi: 10.1503/cmaj.230572.

Continuous glucose monitoring

Stewart B Harris  1 , Basel Bari  2 , Jeremy Gilbert  2
Affiliations

Continuous glucose monitoring

Stewart B Harris et al. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Stewart B. Harris reports research support from AstraZeneca, Eli Lilly, Novo Nordisk and Sanofi. He has also received honoraria or consulting fees from and has participated on advisory boards for Abbott, AstraZeneca, Bayer, Dexcom, Eli Lilly, HLS Therapeutics, Janssen, Novo Nordisk and Sanofi. He has participated in clinical trials for Abbott, Applied Therapeutics, Boehringer Ingelheim, Novartis, Novo Nordisk and Sanofi. Basel Bari has been a member of advisory boards for Novo Nordisk, Sanofi, Boehringer Ingelheim, Astra-Zeneca and Eli Lilly. He has also received grants and honoraria from Master Clinician Alliance, CCRN, Dexcom, Merck, Novo Nordisk, Sanofi, Boehringer Ingelheim, AstraZeneca, Eli Lilly, CPD Network and BD. Jeremy Gilbert reports consulting fees and honoraria from Abbott, Astra Zeneca, Amgen, Boehringer Ingelheim, Dexcom, Eli Lilly, Janssen, Sanofi, Novo Nordisk and HLS Therapeutics, and honoraria from Roche and Master Clinician Alliance. No other competing interests were declared.

References

    1. Diabetes Canada Clinical Practice Guidelines Expert Working Group; Cheng AYY, Feig DS, Ho J, et al. Diabetes Canada Clinical Practice Guidelines Steering Committee. Blood glucose monitoring in adults and children with diabetes: update 2021. Can J Diabetes 2021;45:580–7. - PubMed
    1. Martens T, Beck RW, Bailey R, et al. MOBILE Study Group. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA 2021;325:2262–72. - PMC - PubMed
    1. Edelman SV, Cavaiola TS, Boeder S, et al. . Utilizing continuous glucose monitoring in primary care practice: what the numbers mean. Prim Care Diabetes 2021;15:199–207. - PubMed
    1. Yapanis M, James S, Craig ME, et al. . Complications of diabetes and metrics of glycemic management derived from continuous glucose monitoring. J Clin Endocrinol Metab 2022;107:e2221–36. - PMC - PubMed
    1. Czupryniak L, Dzida G, Fichna P, et al. . Ambulatory glucose profile (AGP) report in daily care of patients with diabetes: practical tips and recommendations. Diabetes Ther 2022;13:811–21. - PMC - PubMed